Detalhe da pesquisa
1.
Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression.
N Engl J Med
; 382(12): 1112-1123, 2020 03 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-32130809
2.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet
; 396(10267): 1994-2005, 2021 12 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-33308425
3.
Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M).
Patient
; 14(6): 849-862, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34056699
4.
Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study.
Lancet HIV
; 8(11): e679-e689, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34648734
5.
Identifying appropriate candidates for long-acting antiretroviral therapy: findings from a survey of health care providers in the ATLAS-2M trial.
HIV Res Clin Pract
; 21(4): 105-113, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33048662
6.
Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials.
J Acquir Immune Defic Syndr
; 85(4): 498-506, 2020 12 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33136751
7.
Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial.
HIV Clin Trials
; 19(4): 129-138, 2018 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-30445896
8.
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial.
Lancet HIV
; 4(8): e331-e340, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28546090
9.
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial.
Lancet Infect Dis
; 15(10): 1145-1155, 2015 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-26201299
10.
Yersinia pseudotuberculosis adhesins regulate tissue-specific colonization and immune cell localization in a mouse model of systemic infection.
Infect Immun
; 74(11): 6487-90, 2006 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-16920785
11.
Distinct mechanisms of integrin binding by Yersinia pseudotuberculosis adhesins determine the phagocytic response of host macrophages.
Cell Microbiol
; 7(10): 1474-89, 2005 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-16153246